GynEC-DX is an in vitro method for diagnosing endometrial cancer by measuring the expression levels of biomarkers in uterine aspirate
GynEC-DX identifies the absence of Type I and Type II cancer, and pre-neoplastic lesions in complex hyperplasia with atypia
GynEC-DX® is an in vitro diagnostic test based on molecular analysis of uterine aspirate samples.
Using a molecular diagnostic method means that the necessary sample size is very little, and since molecular changes precede morphological changes GynEC®-DX can give a reliable diagnosis in an early stage.
Because molecular biology is used, a sample taken for GynEC®-DX is more representative of the lesion than a biopsy taken from a specific location of the endometrium.
GynEC-DX® is not dependent on subjective interpretation of visual histology images from histopathological biopsy assessment.
GynEC-DX® has a negative predictive value of 97%, and 99% if combined with histopathological biopsy assessment.
GynEC®-DX results within 2-4 days.